Dermira, Inc. (NASDAQ:DERM) Director David E. Cohen sold 600 shares of the business’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $26.82, for a total value of $16,092.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of Dermira, Inc. (DERM) traded up $2.20 during mid-day trading on Friday, hitting $29.08. The company’s stock had a trading volume of 447,985 shares, compared to its average volume of 435,675. The company has a debt-to-equity ratio of 0.75, a current ratio of 24.43 and a quick ratio of 24.43.

Dermira (NASDAQ:DERM) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.04). Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. The firm had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1.00 million. sell-side analysts predict that Dermira, Inc. will post -4.15 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was originally published by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/11/03/dermira-inc-derm-director-sells-16092-00-in-stock.html.

A number of equities analysts recently issued reports on DERM shares. Zacks Investment Research cut Dermira from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Needham & Company LLC restated a “buy” rating and set a $46.00 price objective on shares of Dermira in a report on Tuesday, July 18th. Mizuho restated a “buy” rating and set a $43.00 price objective (up previously from $40.00) on shares of Dermira in a report on Thursday, September 7th. Cantor Fitzgerald reiterated a “buy” rating and issued a $45.00 target price on shares of Dermira in a report on Tuesday, September 26th. Finally, BidaskClub upgraded Dermira from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 16th. Four investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $44.40.

Hedge funds have recently modified their holdings of the business. BNP Paribas Arbitrage SA lifted its holdings in shares of Dermira by 2,220.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 3,975 shares during the period. SG Americas Securities LLC raised its position in shares of Dermira by 66.8% in the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 2,203 shares in the last quarter. KCG Holdings Inc. bought a new position in shares of Dermira in the 1st quarter worth $215,000. Legal & General Group Plc raised its position in shares of Dermira by 16.3% in the 1st quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock worth $236,000 after acquiring an additional 963 shares in the last quarter. Finally, Ardsley Advisory Partners bought a new position in shares of Dermira in the 2nd quarter worth $291,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.